ROCKVILLE, Md., April 10, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the appointment of Amy B. Fix to the position of Vice President of Regulatory Affairs. She is responsible for directing regulatory strategy and coordinating the company's interactions with regulatory agencies which oversee the development and commercialization of its vaccine product candidates.
Before joining Novavax, Ms. Fix held regulatory-affairs positions of increasing responsibility at some of the leading vaccine pharmaceutical companies, including MedImmune and Baxter International, where she was Head of Global Regulatory Affairs Vaccines and led the regulatory strategy for Baxter's seasonal and pandemic vaccines under a contract with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). Most recently, she was Senior Director of Regulatory Affairs at Emergent Biosolutions where she was responsible for international licensure of its anthrax vaccine and management of the regulatory activities associated with its BARDA-supported advanced development and manufacturing program. Ms. Fix received a bachelor's degree in biology from the University of Illinois, Urbana-Champaign, a master's degree in molecular biology from the University of Virginia's Biotechnology program, and a master's degree in business administration from the Johns Hopkins University.
"Amy has considerable expertise in the development of novel vaccines and will be an important guide for us as we advance our vaccine candidates through regulatory review," said Stanley C. Erck, President and CEO of Novavax. "She will play an integral role in supporting our clinical development programs, coordinating our interactions with regulatory agencies and preparing us for the commercial launch of our vaccine product candidates. I welcome her to Novavax and look forward to her contributions to our future success."About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platform to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH. Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website, www.novavax.com .
CONTACT: Frederick W. Driscoll VP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts